Structured Treatment Interruption in Patients with Alveolar Echinococcosis

Hepatology

Volumn 39, Issue 2, 2004, Pages 509-517

  Reuter, Stefan ^a   Buck, Andreas ^a   Manfras, Burkhard ^a   Kratzer, Wolfgang ^a   Seitz, Hanns Martin ^b   Darge, Kassa ^c   Reske, Sven Norbert ^a   Kern, Peter ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ECHINOCOCCOSIS; ECHINOCOCCUS MULTILOCULARIS; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LUNG ALVEOLUS; LUNG HYDATID CYST; MALE; NONHUMAN; PARAMETER; PARASITOLOGY; PATHOLOGY; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SCINTISCANNING; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTHELMINTICS; BENZIMIDAZOLES; ECHINOCOCCOSIS, PULMONARY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PULMONARY ALVEOLI; RECURRENCE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1242291928     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20078     Document Type: Article

References (36)

1. Ishizu H, Uchino J, Sato N, Aoki S, Suzuki K, Kuribayashi H. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. HEPATOLOGY 1997;25:528-531.
2. WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ 1996;74:231-242.
3. Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. HEPATOLOGY 1994;19:735-742.
4. Schantz PM, Wilson JF, Wahlquist SP, Boss LP, Rausch RL. Serologic tests for diagnosis and post-treatment evaluation of patients with alveolar hydatid disease (Echinococcus multilocularis). Am J Trop Med Hyg 1983;32:1381-1386.
5. Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992;15:234-249.
6. Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 1998;29:994-998.
7. Reuter S, N̈ussle K, Kolokythas O, Haug U, Rieber A, Kern P, Kratzer W. Alveolar iver echinococcosis: a comparative study of three imaging techniques. Infection 2001;29:119-125.
8. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-1969.
9. Bangerter M, Moog F, Griesshammer M, Merkle E, Hafner M, Ellenrieder V, Reske SN, et al. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver. Int J Hematol 1997;66:517-520.
10. Schroter G, Schneider EJ, Schwaiger M. Assessment of tissue viability with fluorine-18-fluoro-2-deoxyglucose (FDG) and carbon-11-acetate PET imaging. Herz 1994;19:42-50.
11. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, Nakamura K, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 1996;10:185-191.
12. De Winter F, Vogelaers D, Gemmel F, Dierckx RA. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002;21:247-257.
13. Alavi A, Zhuang H. Finding infection-help from PET. Lancet 2001;358:1386.
14. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000;27:822-832.
15. Reuter S, Schirrmeister H, Kratzer W, Dreweck C, Reske SN, Kern P. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis 1999;29:1157-1163.
16. Gottstein B, Jacquier P, Bresson-Hadni S, Eckert J. Improved primary immunodiagnosis of alveolar echinococcosis in humans by an enzyme-linked immunosorbent assay using the Em2plus antigen. J Clin Microbiol 1993;31:373-376.
17. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994;21:930-936.
18. Ammann RW, Hirsbrunner R, Cotting J, Steiger U, Jacquier P, Eckert J. Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results). Am J Trop Med Hyg 1990;43:506-515.
19. Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 2000;46:451-456.
20. Rausch RL, Wilson JF, McMahon BJ, O'Gorman MA. Consequences of continuous mebendazole therapy in alveolar hydatid disease-with a summary of a ten-year clinical trial. Ann Trop Med Parasitol 1986;80:403-419.
21. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, Taniguchi M, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:1016-1020.
22. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, et al. Evaluation of liver tumors using fluorine-18-fluorode-oxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339.
23. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
24. Choji K, Fujita N, Chen M, Spiers AS, Morita Y, Shinohara M, Nojima T, et al. Alveolar hydatid disease of the liver: computed tomography and transabdominal ultrasound with histopathological correlation. Clin Radiol 1992;46:97-103.
25. Didier D, Weiler S, Rohmer P, Lassegue A, Deschamps JP, Vuitton D, Miguet JD, et al. Hepatic alveolar echinococcosis: correlative US and CT study. Radiology 1985;154:179-186.
26. Liu YH, Wang XG, Chen YT, Yao YQ. Computer tomography of liver in alveolar echinococcosis treated with albendazole. Trans R Soc Trop Med Hyg 1993;87:319-321.
27. Ammann RW, Tschudi K, von Ziegler M, Meister F, Cotting J, Eckert J, Witassek F, et al. [Long term course of alveolar echinococcosis in 60 patients treated by mebendazole (1976-1985)]. Klin Wochenschr 1988;66:1060-1073.
28. Rausch RL, Wilson JF, Schantz PM, McMahon BJ. Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. Am J Trop Med Hyg 1987;36:576-585.
29. Gottstein B, Mesarina B, Tanner I, Ammann RW, Wilson JF, Eckert J, Lanier A. Specific cellular and humoral immune responses in patients with different long-term courses of alveolar echinococcosis (infection with Echinococcus multilocularis). Am J Trop Med Hyg 1991;45:734-742.
30. Jura H, Bader A, Frosch M. In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 1998;42:1052-1056.
31. Rausch RL, Wilson JF, McMahon BJ, O'Gorman MA. Consequences of continuous mebendazole therapy in alveolar hydatid disease-with a summary of a ten-year clinical trial. Ann Trop Med Parasitol 1986;80:403-419.
32. Reuter S, Merkle M, Brehm K, Kern P, Manfras B. Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrob Agents Chemother 2003;47:620-625.
33. Eckert J. Prospects for treatment of the metacestode stage of Echinococcus. In: Thompson RCA, ed. The Biology of Echinococcus and Hydatid Disease. London: George Allen & Unwin, 1986:250-284.
34. Vuitton DA, Guerret-Stocker S, Carbillet JP, Mantion G, Miguet JP, Grimaud JA. Collagen immunotyping of the hepatic fibrosis in human alveolar echinococcosis. Z Parasitenkd 1986;72:97-104.
35. Chakrabarti R, Jung CY, Lee TP, Liu H, Mookerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 1994;152:2660-2668.
36. Gamelli RL, Liu H, He LK, Hofmann CA. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996;59:639-647.